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We determined the in vitro activity of SMT19969 and 11 comparators, including metronidazole, vancomycin, and fidaxomicin,
against 107 C. difficile isolates of different antimicrobial resistance phenotypes. Fidaxomicin and SMT19969 were the most ac-
tive. The fidaxomicin and SMT19969 geometric meanMICs were highest in ribotypes known to showmultiple resistance. Core-
sistance to linezolid andmoxifloxacin was evident in ribotypes 001, 017, 027, and 356. The high-level ceftriaxone resistance in
ribotypes 356 and 018 was location linked.
Clostridiumdifficile infection (CDI) is a significant cause of nos-ocomial diarrhea and a continuing burden on health care re-
sources (1). Most antimicrobials have been associated with CDI
cases at some point, including the treatment agents vancomycin
and metronidazole (Clostridium difficile Ribotyping Network
[CDRN] for England and Northern Ireland 2011-2013; https:
//www.gov.uk/government/publications/clostridium-difficile
-ribotyping-network-cdrn-report). CDI recurrence is common
following conventional antimicrobial treatment and is associated
with reduced gut bacterial diversity (2). Treatment options re-
main limited, despite the introduction of fidaxomicin for CDI;
therefore, development of novel antimicrobial agents, particularly
ones with a lower potential for gut microbiota depletion, is
needed. SMT19969 is a novel antimicrobial with potent in vitro
activity against C. difficile (3) but limited activity against gut mi-
croflora (4). We investigated the activity of SMT19969 and 11
comparators, including predisposing and treatment agents,
against C. difficile isolates of different antimicrobial resistance
phenotypes.
A panel of 107C. difficile isolates was selected from a collection
assembled during the ClosER study (5) by permission of Astellas
Pharma Europe. Clinical isolates were collected between July 2011
and April 2013 and were selected to maximize the diversity of
antimicrobial resistance phenotypes. The susceptibilities ofC. dif-
ficile isolates to metronidazole, vancomycin, fidaxomicin, rifam-
pin, moxifloxacin, clindamycin, imipenem, chloramphenicol,
tigecycline, SMT19969, linezolid, and ceftriaxone were deter-
mined using a Wilkins-Chalgren agar incorporation method (5,
6). The MIC was defined as the lowest dilution at which growth
was completely inhibited or at which only single colonies re-
mained.
The MIC results for each isolate were designated susceptible
(S), intermediately resistant (I), fully resistant (R), or reduced
susceptibility (RS) according to the breakpoints defined in Table
1. The breakpoints were established according to the Clinical Lab-
oratory Standards Institute (CLSI), the European Committee on
Antimicrobial Susceptibility Testing (EUCAST), or published
data. Each result was assigned a score (S 0, I 1, and R 2). A
cumulative resistance score (CRS), based on susceptibility to each
of the 11 antimicrobials tested, was generated for each isolate.
Thus, an isolate that was fully susceptible to 6, intermediately
resistant to 2, and resistant to 3 antimicrobials would generate a
score of 8 (0 0 0 00 0 1 1 2 2 2).
Fidaxomicin was the most active agent, followed by
SMT19969, with similar geometric mean (GM) MICs (0.04 mg/
liter versus 0.07 mg/liter, respectively) (Table 1) and with no evi-
dence of resistance to either agent (Table 1). Fidaxomicin (GM
MIC of 0.04 mg/liter) was 10- and 20-fold more active than met-
ronidazole (GMMICof 0.41mg/liter) and vancomycin (GMMIC
of 0.80mg/liter), while SMT19969 (GMMICof 0.07mg/liter) was
6- and 11-fold more active, respectively. The MICs of both fidax-
omicin and SMT19969 were comparable to those observed previ-
ously (3, 5, 7, 8). Although the fidaxomicin MICs were slightly
higher among the highly related ribotype (RT) 027 (n 22) and
RT198 (n 8) isolates (GM MIC of 0.08 mg/liter for both) than
for all isolates (0.04 mg/liter), this was not statistically significant
(Kruskal-Wallis P 0.86 and 1.00, respectively). Conversely, the
fidaxomicin MICs were statistically significantly lower among
RT001 isolates (Kruskal-Wallis P  0.0001), with a GM MIC of
0.01 mg/liter, reflecting previous results (5, 7, 8). The SMT19969
MICs for RT027 (GM  0.11 mg/liter) and RT017 (GM  0.12
mg/liter) isolates were slightly elevated above those for all isolates,
but this was not statistically significant (Kruskal-Wallis P  0.30
and 0.29, respectively). Ribotypes 027, 198, and 017 were associ-
atedwithmultiple antimicrobial resistance in a previous study (5).
The slightly elevated fidaxomicin and SMT19969 GM MICs ob-
served against selected ribotypes are unlikely to have clinical sig-
nificance, given the high intraluminal gastrointestinal (GI) con-
centrations of both agents (9, 10). The GM metronidazole MICs
were also slightly higher among RT027 and RT198 (1 mg/liter for
both) isolates than those for all isolates (0.4 mg/liter), in line with
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previous observations (5, 8). However, despite low gut concentra-
tions, metronidazole treatment failure has not been linked to de-
creased susceptibility to this agent (8).
There was a significant correlation between increased CRS and
increased SMT19969 MICs (Pearson’s product-moment correla-
tion r  0.33; P  0.004), metronidazole MICs (r  0.27; P 
0.004), and, to a lesser degree, fidaxomicin MICs (r  0.25; p 
0.01), butno such correlation for vancomycin (r0.12;P0.21).A
comparison of susceptibilities by ribotype in this study would in-
evitably contain bias, given that the selection criteria were based
on the resistance phenotypes; however, it is worth noting that the
C. difficile isolates with the highest MICs of SMT19969 belonged
to ribotypes noted for resistance to multiple antimicrobials.
Isolates were selected to represent a broad range of antimicro-
bial resistance phenotypes. The results for metronidazole, vanco-
mycin, fidaxomicin, rifampin, moxifloxacin, clindamycin, chlor-
amphenicol, and tigecycline largely reflected those previously
determined (5), with evidence of high-level resistance to rifampin,
moxifloxacin, clindamycin, and chloramphenicol (Table 1). Imi-
penem resistance was low (3.7%), and reduced susceptibility to
tigecycline was very rare (1%). Most isolates were linezolid sus-
ceptible (85.3%), but, unexpectedly, 13.8% showed high-level re-
sistance (16 mg/liter). These isolates belonged to RT001 (7 of
22), RT017 (2 of 7), RT027 (4 of 22), and RT356 (2 of 4). There
was location clustering in RT001, with 3 linezolid-resistant iso-
lates from the same geographical location. These isolates also
showed resistance to clindamycin and in some cases chloram-
phenicol (Table 2). A recent publication also described linezolid
resistance among RT001, RT078, RT126, and RT017 isolates from
Spain (11). The authors demonstrated the presence of the multi-
drug resistance gene, cfr, in isolates showing high-level resistance
to chloramphenicol, erythromycin, clindamycin, and linezolid
from RT017, RT078, and RT126. This was linked to a mobile
genetic element, Tn6218, indicating the possibility of transmis-
sion between strains. They were unable to demonstrate the pres-
ence of cfr in the remaining RT001 isolates that showed lower
chloramphenicol MICs, suggesting that other resistance mecha-
nisms are involved (11). There is likely to be more than one etiol-
ogy for the linezolid resistance seen in the isolates tested here,
given the phenotypes displayed. It is interesting to note that all of
the linezolid-resistant isolates also displayed moxifloxacin resis-
tance. This combination was associated with higher cadazolid
MICs (2- to 4-fold higher than those of susceptible isolates with
resistance to eithermoxifloxacin or linezolid) (12) andmay not be
unexpected since cadazolid is an oxazolidinone-fluoroquinolone
hybrid molecule. However, its clinical significance is unknown,
given the high fecal cadazolid concentrations achieved (13).
Only 6% of isolates were susceptible to ceftriaxone (GM MIC
of 58.2mg/liter) according to the breakpoints used (14). The high-
est levels of resistance (128mg/liter) were seen in RT356 isolates
(all) and in 5 of 10 RT018 isolates, which are closely related. Ri-
botype 356 is exclusive to Italy, and all 5 RT018 isolates showing
MICs of 128 mg/liter were also from this location. This high-
level ceftriaxone resistance adds to the previously reported multi-
drug resistance inRT018 andRT356 isolates from Italy (5). Twoof
the RT356 isolates also showed intermediate imipenem resistance
(Table 2).
In summary, SMT19969 was highly active against more than
100 isolates displaying different antimicrobial resistance pheno-
types. There was no evidence of SMT19969 or fidaxomicin resis-T
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tance, but some evidence of modestly higher SMT19969 and
fidaxomicinMICs among ribotypes previously noted for multiple
antimicrobial resistance. Linezolid resistance was more prevalent
than expected and was also associated with ribotypes noted for
multidrug resistance phenotypes. High-level ceftriaxone resis-
tance was found in multiresistant RT018 and RT356 isolates from
Italy.
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